[Indications and results of monoamine treatment in parkinsonian syndromes].
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001545:Benserazide / Q000494:pharmacology; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005190:Family; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D009765:Obesity; D010300:Parkinson Disease / Q000188:drug therapy* / Q000628:therapy; D026741:Physical Therapy Modalities; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D004338:Drug Combinations; D004295:Dihydroxyphenylalanine; D001545:Benserazide; D002262:Carboxy-Lyases
Indications et résultats du traitement par les monoamines dans les syndromes parkinsoniens.